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Background: A direct comparison of severe acute respiratory syndrome coronavirus 2 positive patients
with a severe acute respiratory syndrome coronavirus 2 negative control group undergoing an operative
intervention during the current pandemic is lacking, and a reliable estimate of the assumed difference in
morbidity and mortality between both patient categories remains unknown.
Methods: We included all consecutive patients with a confirmed pre- or postoperative severe acute
respiratory syndrome coronavirus 2 positive status (operated in 27 hospitals) and negative control pa-
tients (operated in 4 hospitals) undergoing emergency or elective operations. A propensity score-
matched comparison of clinical outcomes was performed between severe acute respiratory syndrome
coronavirus 2 positive and negative tested patients (control group). Primary outcome was overall 30-day
mortality rate between both groups. Main secondary outcomes were overall, pulmonary, and throm-
boembolic complications.
Results: In total, 161 severe acute respiratory syndrome coronavirus 2 positive and 342 control severe acute
respiratory syndrome coronavirus 2 negative patients were included in this study. The 30-day overall post-
operative mortality rate was greater in the severe acute respiratory syndrome coronavirus 2 positive cohort
compared with the negative control group (16% vs 4% respectively; P ¼ .007). After propensity score matching,
the severe acute respiratory syndrome coronavirus 2 positive group consisted of 123 patients (median 70 years
of age [interquartile range 59e77] and 55% male) were compared with 196 patients in the matched control
group (median 69 years (interquartile range 58e75] and 53% male). The 30-day mortality rate and risk were
greater in the severe acute respiratory syndrome coronavirus 2 positive group compared with the matchedh Surgical COVID-19 Research
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P.K.C. Jonker et al. / Surgery 169 (2021) 264e274 265control group (12% vs 4%; P¼ .009 and odds ratio 3.4 [95% confidence interval 1.5e8.5]; P¼ .005, respectively).
Overall, pulmonary and thromboembolic complications occurred more often in severe acute respiratory syn-
drome coronavirus 2 positive patients (P < .01).
Conclusion: Patients diagnosed with perioperative severe acute respiratory syndrome coronavirus 2 have
an increased risk of 30-day mortality, pulmonary complications, and thromboembolic events. These
findings serve as an evidence-based argument to postpone elective surgery and selected emergency cases.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
The worldwide pandemic of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has caused over 9 million registered
coronavirus disease 2019 (COVID-19) cases and led to major dis-
ruptions of the global health care system.1 During the current peak
of the pandemic, surgical theatres and recovery areas have been
converted to intensive care unit (ICU) facilities to treat patients
with SARS-CoV-2 infections.2 As a consequence, the global capacity
for elective surgical care has decreasedmarkedly with an estimated
number of 2.4 million cases per week.3 Nevertheless, surgical
emergency and urgent elective procedures needed to be continued
in endemic areas. A recently published study of 1,128 patients with
perioperative SARS-CoV-2 infections undergoing an operation in
various health care systems across the world reported a 30-day
postoperative overall mortality rate of 24%.4 Pulmonary complica-
tions were reported in 51% of patients. The 24% mortality rate in
SARS-CoV-2 positive patients is unusually high compared with
routine reported rates in similar elective and emergency operations
before the pandemic.5,6 Recently, a retrospective, case-control
study from Italy reported a 20% 30-day postoperative overall-
mortality rate (odds ratio [OR] 9.5, 95% confidence interval [CI]
1.8e96.5) and a greater risk of pulmonary complications (OR 35.6,
95% CI 9.3e205.6) and thromboembolic complications (OR 13.2,
95% CI 1.5e∞) in 41 SARS-CoV-2 positive patients compared with a
mainly historical control cohort.7 Although of relevance, this single-
center study has limitations owing to the small sample of SARS-CoV-
2 positive patients and the overall design resulting in inaccurate
estimates. It is, therefore, important to provide clinicians with more
accurate data to improve perioperative clinical decision-making for
this patient category during the foreseen new waves of SARS-CoV-2
infections. This current multicenter, nationwide, matched-cohort
study compares the 30-day postoperative morbidity and mortality
rates between SARS-CoV-2 positive and negative patients undergo-
ing elective or emergency operations in hospitals within a similar
health care system and standardized surgical guidelines. Results of
this study will provide a more reliable insight into the actual dif-
ference in overall mortality and complications between patients
with and without perioperative SARS-CoV-2 infection.
Methods
Setting
This nationwide, multicenter, observational, cross-sectional
retro- and prospective cohort study was conducted in the
Kingdom of the Netherlands. The study protocol was designed at
the University Medical Center Groningen (UMCG) and approved
after an expedited review by the respective local ethical review
committees of participating centers (METc 2020/170, non-WMO
approval). Data transfer agreements between UMCG and partici-
pating centers were established. Informed consent of included
patients was acquired in linewith local regulations. Dutch surgeons
were informed about this study with regular updates via the Dutch
Surgical Society. From the first week of April, nationwide, routine,preoperative screening by quantitative reverse transcription poly-
merase chain reaction (RT-PCR) with or without a computed to-
mography (CT) of the chest was implemented per standard of care.8
The SARS-CoV-2 positive cohort was established from consecutive
patients with a pre- or postoperative SARS-CoV-2 positive status
who underwent an operation between February 27 and June 1,
2020 in 27 centers across the Kingdom of the Netherlands, covering
10 out of 12 provinces. The negative control group was recruited at
4 of the 27 centers (Hospital Bernhoven [Uden], Medical Center
Leeuwarden [Leeuwarden], Radboud University Medical Center
[Nijmegen], and UMCG [Groningen]) consisting of consecutive
SARS-CoV-2 negative patients who underwent routine preopera-
tive SARS-CoV-2 RT-PCR screening. These 4 centers (2 teaching
hospitals and 2 tertiary referral centers) were chosen intentionally
and spread across the country to include geographic areas with
different incidence rates of SARS-CoV-2.When no 30-day follow-up
was planned, patients were contacted per phone by coordinating
researchers to acquire final follow-up status.
Inclusion and exclusion criteria
Patients eligible for inclusion in the SARS-CoV-2 positive cohort
either had a SARS-CoV-2 positive RT-PCR test (nasopharyngeal or
throat swab) or a strong clinical suspicion combined with a CT of the
chest defined as suspect for SARS-CoV-2 infection 30 days before
surgery or within 30 days postoperatively. Patients eligible for in-
clusion in the control group had a negative SARS-CoV-2 history,
tested negative for SARS-CoV-2 during preoperative screening with
RT-PCR, and remained negative during the 30-days of follow-up. The
SARS-CoV-2 status during follow-upwas assessed clinically based on
symptomatology, without routine RT-PCR screening of asymptom-
atic patients. Patients of all ages and all surgical subspecialties were
included in both cohorts on the condition of availability of completed
30-day follow-up. Patients were excluded when data were insuffi-
cient or follow-up information could not be completed.
Data acquisition and management
Data were collected and managed using the REDCap electronic
data capture tool (version 8.10.18; Vanderbilt University, Nashville,
TN).9 Pseudo anonymized data was entered manually from the
electronic patient file in the electronic case report form by local
researchers of the respective participating centers and cross-
checked for inconsistencies and missing data by the coordinating
researchers before data locking. Per site, a deidentification key was
stored in an on-site, secured, digital data storage area. Center-
specific data were accessible by local researchers and the coordi-
nating researchers from the UMCG (S.K., P.K.C.J., W.Y.vdP., P.J.S.,
J.P.P.M.dV.). Before analysis, parameters were checked for comple-
tion per case, and data were curated by coordinating researchers.
Study parameters
Baseline patient demographics, comorbidity status, and drug
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Fig 1. Study flowchart.
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first of May was acquired from the Dutch government.10 Clinical
symptoms at SARS-CoV-2 diagnosis were scored. The Charlson
comorbidity index was calculated.11 Operative procedures were
graded with the surgical risk stratification from the University of
California Los Angeles, a numerical value to reflect the risk level
associated with the operation ranging from 1 (very low risk) to 5
(very high risk).12 Overall survival, SARS-CoV-2 infection status, and
complication rates (according to the Clavien-Dindo classification
and summarized by the Comprehensive Complication Index) were
scored at 30 days from the index operation.13,14 Pulmonary com-
plications were diagnosed either clinically (ie, respiratory insuffi-
ciency) or with imaging (ie, pneumonia, acute respiratory distress
syndrome). Clinically diagnosed thromboembolic complications
were confirmed with imaging.
Study end points
The primary endpoint was defined as the overall, 30-day post-
operative mortality rate. As secondary outcomes, complication rate,
complication severity, pulmonary complications, and thrombo-
embolic events were compared between the matched cohorts.
Statistical analysis
Bivariate frequencies were calculated for the descriptive anal-
ysis. Missing data were included in the descriptive analyses. The c2
test was used for categorical data, and logistic modeling was used
for calculating ORs with 95% CIs. Propensity score matching was
used to help control for differences at baseline between thosepatients undergoing an operation who had a preoperative SARS-
CoV-2 infection or who developed a SARS-CoV-2 infection within
the immediate 30 days postoperatively and those patients under-
going an operation without SARS-CoV-2 infection confirmed pre or
postoperatively. Cohorts were matched by age, sex, body mass in-
dex, smoking status, preoperative comorbidities (diabetes, hyper-
tension, congestive heart failure, myocardial infarction, peripheral
vascular disease, cerebrovascular events, chronical renal disease,
cancer, transplant), immunosuppressive medication, Eastern
Cooperative Oncology Group score, Charlson comorbidity index,
American Society of Anesthesiologists (ASA) classification, type of
anesthesia, and surgical risk score. The individual propensities for
infection with SARS-CoV-2 were estimated with the use of a
multivariable logistic regression model that included all baseline
covariates. In the propensity score-matching analysis, the nearest-
neighbor method was applied with a caliper of .25 to create a
matched control sample. Various matching strategies were
explored. These strategies included matching with or without
replacement of patients, with or without re-estimation of the
propensity scores during matching, and matching smallest or
largest distance first. Assessment of the covariate balance was done
by comparing standardized differences before and after matching.
The analysis of the primary and secondary outcomes was done by
using the matched sample. Multiple imputationwas used to handle
missing data, and model estimates and standard errors were
calculated with Rubin’s rules.15 Finally, a subgroup analysis was
performed including only patients with a SARS-CoV-2 positive
status diagnosed either 7 days pre- or postoperatively. Statistical
analysis was performed using R version 4.0.0 (R Foundation for
Statistical Computing, Vienna, Austria). Imputation was done using
the mice-package and matching was done using the MatchIt-
package (R Foundation for Statistical Computing).16,17
Results
Description of the cohort
A total of 558 patients undergoing an operation during the
pandemic were screened for study inclusion. Ultimately, 161 SARS-
CoV-2 positive and 342 SARS-CoV-2 negative control patients with
complete 30-day postoperative follow-up were included in the
unmatched cohort (Fig 1). Baseline characteristics of the included
patients are shown in Table I. The 342 SARS-CoV-2 negative pa-
tients underwent operative intervention in Hospital Bernhoven (23
[7%]), Medical Center Leeuwarden (124 [36%]), UMCG (93 [27%]),
and at the Radboud University Medical Center (102 [30%]). After
propensity matching, a matched cohort of 123 SARS-CoV-2 positive
and 196 SARS-CoV-2 negative control patients was established
(Table I). The distribution of the estimated propensity scores for a
positive SARS-CoV-2 status among SARS-CoV-2 positive and
negative control patients is shown in Supplemental Fig 1. ORs for a
positive SARS-CoV-2 status according to all the variables included
in the propensity score model are shown in Supplemental Table I.
The C-statistic for the model was 0.78. The differences between
SARS-CoV-2 status and baseline variables were attenuated in the
propensity score-matched samples as compared with the un-
matched samples (Supplemental Fig 2). An overview of operative
procedures in the unmatched and matched cohorts is provided in
Supplemental Table II.
SARS-CoV-2 positive patients
The 161 patients with perioperative SARS-CoV-2 positive status
underwent operations in 27 centers. Distribution of participating
centers across the Netherlands combined with the prevalence of
Table I
Baseline characteristics of the unmatched and propensity score-matched patient groups
Unmatched patients Propensity score-matched patients*
SARS-CoV-2 positive
patients n ¼ 161
SARS-CoV-2 negative
patients n ¼ 342
SARS-CoV-2 positive
patients n ¼ 123
SARS-CoV-2 negative
patients n ¼ 196
Age categoryeno (%)
<50 y 14 (8.7) 89 (26.0) 13 (10.6) 19 (9.7)
50e<70 y 51 (31.7) 138 (40.4) 47 (38.2) 80 (40.8)
70 y 95 (59.0) 115 (33.6) 63 (51.2) 97 (49.5)
Female sexeno (%) 72 (44.7) 161 (47.1) 56 (45.5) 93 (47.4)
BMIeno (%)
<18.5 7 (4.3) 29 (8.5) 6 (4.9) 10 (5.1)
18.5e<25 49 (30.4) 117 (34.2) 41 (33.3) 65 (33.2)
25e<30 46 (28.6) 112 (32.7) 39 (31.7) 66 (33.7)
30e<35 32 (19.6) 49 (14.3) 24 (19.5) 38 (19.4)
35e<40 12 (7.5) 21 (6.1) 10 (8.1) 15 (7.7)
40 5 (3.1) 3 (0.9) 3 (2.4) 2 (1.0)
Missing 10 (6.2) 11 (3.2) 0 0
Current smokereno (%) 18 (11.2) 47 (13.7) 18 (14.6) 33 (16.8)
Missing 33 (20.5) 71 (20.8) 0 0
Diabeteseno (%) 44 (27.3) 42 (12.3) 22 (18) 35 (18)
Hypertensioneno (%) 80 (49.7) 105 (30.7) 53 (43.1) 87 (44.4)
Missing 0 (0.0) 13 (3.8) 0 0
Congestive heart failureeno (%) 13 (8.1) 19 (5.6) 8 (6.5) 13 (6.6)
Myocardial infarcteno (%) 21 (13.0) 24 (7.0) 12 (9.8) 19 (9.7)
Peripheral vascular diseaseeno (%) 26 (16.1) 40 (11.7) 16 (13) 27 (14)
Chronic pulmonary diseaseeno (%) 20 (12..4) 26 (7.6) 10 (8.1) 20 (10)
CVAeno (%) 24 (14.9) 31 (9.1) 13 (11) 21 (11)
Chronic renal diseaseeno (%) 22 (13.7) 25 (7.3) 10 (8.1) 16 (8.2)
Cancereno (%) 30 (18.6) 123 (36.0) 27 (22) 47 (24)
Transplanteno (%) 1 (0.6) 7 (2.0) 1 (0.8) 1 (0.5)
Missing 2 (1.2) 2 (0.6) 0 0
Immunosuppressioneno (%) 10 (6.2) 17 (5.0) 9 (7.3) 10 (5.1)
Missing 0 6 (1.8) 0 0
ECOG score
0e1 93 (57.8) 288 (84.2) 92 (75) 155 (79)
2 26 (16.1) 29 (8.5) 21 (17) 25 (13)
3e4 30 (18.6) 18 (5.3) 10 (8.1) 16 (8.2)
Missing 12 (7.5) 7 (2.0) 0 0
Charlson comorbidity indexemedian (IQR) 4 (2e7) 4 (2e6) 4 (2e6) 4 (2e6)
Missing 0 (0.0) 1 (0.3) 0 0
ASA classificationeno (%)
IeII 60 (37.3) 169 (49.4) 54 (44) 87 (44)
IIIeIV 97 (60.2) 170 (49.7) 69 (56) 109 (56)
Missing 4 (2.5) 3 (0.9) 0 0
Anesthesiaeno (%)
General 118 (73.3) 291 98 (80) 156 (80)
Other (including spinal) 43 (26.7) 51 25 (20) 40 (20)
Missing 0 (0.0) 0 (0.0) 0 0
Type of operationeno (%)
Elective 87 (54.0) 252 (73.7) 76 (62) 131 (67)
Emergency 73 (45.3) 84 (24.6) 47 (38) 65 (33)
Missing 1 (0.6) 6 (1.8) 0 0
Surgical risk scoreeno (%)
1e2 42 (26.1) 72 (21.1) 35 (29) 48 (25)
3 64 (39.8) 135 (39.5) 47 (38) 86 (44)
4 36 (22.4) 100 (29.2) 31 (25) 48 (25)
5 10 (6.2) 31 (9.1) 10 (8.1) 14 (7.1)
Missing 9 (5.6) 4 (1.2) 0 0
BMI, body mass index; CVA, cerebrovascular accident; ECOG, Eastern Cooperative Oncology Group.
* Data for patients included in the propensity-scoreematched analysis were multiply imputed.
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2020 is presented in Fig 2. The majority of SARS-CoV-2 positive
patients was male (89 [55%]) with a median age of 72 years (inter-
quartile range [IQR] 62e78). Patients with a perioperative SARS-
CoV-2 infection underwent mainly elective operations (87 [54%])
with general anesthesia (118 [73%]), as shown in Table I; themajority
of patients (92 [57%]) was diagnosed postoperatively with SARS-
CoV-2. In case of preoperative diagnosis, median time from
SARS-CoV-2 diagnosis to operation was 8 days (IQR 2e22 days). For
the 92 patients diagnosed postoperatively, median time from the
operation to diagnosis was 8 days (IQR 3e17 days). The diagnosis ofSARS-CoV-2wasmadewith positive RT-PCR (150 [93%]) or a chest CT
highly suspicious for SARS-CoV-2 in combination with clinical
symptoms (11 [7%]). Eleven patients (7%) had an asymptomatic
presentation at diagnosis but tested positive by RT-PCR. Eighty-
seven percent of SARS-CoV-2 positive patients (n ¼ 140) presented
with 1 or more symptoms. The 5 most prevalent symptoms at
diagnosis were fever (94 [58%]), cough (84 [52%]), tiredness (74
[46%]), dyspnea (66 [41%]), and abdominal pain (26 [23%]). SARS-
CoV-2 positive patients received treatment on the ward (101
[63%]), in the ICU (40 [25%]), at home quarantine, in a nursing home,
in a rehabilitation center (17 [11%]), or at an unknown location (3











cases per 1,000 people
Fig 2. Distribution of participating centers across the Netherlands and the prevalence of confirmed SARS-CoV-2 positive people per 1,000 habitants per municipality as per June 16,
2020.
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required in 33 patients (21%), and no extracorporeal membrane
oxygenation was performed. According to the primary outcome
(survivor versus nonsurvivor), more details of the unmatched SARS-
CoV-2 group are listed in Table II. Of the nonsurvivor group (n ¼ 26),
patients were generally older. Deceased patients had diabetes, hy-
pertension, or peripheral vascular disease more frequently. Addi-
tionally, they had a worse Eastern Cooperative Oncology Group
performance status and higher ASA classification. No difference was
found in the proportion of patients who underwent emergency
operations or elective operations among the 2 groups (45% emer-
gency surgery in the SARS-CoV-2 positive survivors versus 46%
emergency surgery in the SARS-CoV-2 nonsurvivors; P¼ .99). Finally,
there was no difference in the proportion of symptomatic patients in
the nonsurvivor group comparedwith the patientswhowere alive at
30-days follow-up.Primary outcome
Before propensity matching, the 30-day overall postoperative
mortality rate in SARS-CoV-2 positive and negative patients was
16% and 4%, respectively (P ¼ .007; Table III). In the propensity
score-matched cohort, 30-day overall mortality was associated
with an OR of 3.4 (95% CI 1.5e8.5) for patients with a perioperative
SARS-CoV-2 positive status compared with negative control pa-
tients. The overall 30-day postoperative mortality rates for both
matched and unmatched cohorts are provided in Table III. In the
subgroup of patients with a SARS-CoV-2 positive status diagnosed
either 7 days pre- or postoperatively, an increase in mortality ratecomparedwith SARS-CoV-2 negative patients was confirmed (n¼ 8
[12%] vs. n ¼ 14 (4%); P ¼ .009).Secondary outcomes
Patients with perioperative SARS-CoV-2 had more complica-
tions (1 [IQR 0e3] vs 0 [IQR 0e1]; P < .001) with a higher
comprehensive complication index (21 [IQR 0e40]) vs 0 [IQR
0e12]; P < .001) compared with matched negative control patients.
The number of grade II and grade IV complications was greater in
the matched SARS-CoV-2 positive cohort (P < .01). Pulmonary
complications occurred in 25 (20%) SARS-CoV-2 positive patients
and in 6 (3%) matched SARS-CoV-2 negative patients (P < .001).
Similarly, the number of patients with thromboembolic events was
greater in the SARS-CoV-2 positive group (8 [7%]) compared with
the matched negative control group (1 [0.5%]; P ¼ .004). There was
no difference in hemorrhagic or infectious complications between
matched cohorts. An overview of the complications for matched
and unmatched cohorts is provided in Table III. Supplemental
Table III gives a detailed description of the diagnosed pulmonary
complications and thromboembolic events.Discussion
This nationwide, cohort study compares morbidity and mor-
tality rates betweenmatched patients with and without SARS-CoV-
2 infection undergoing emergency or elective operations during the
first wave of the pandemic. We found that a pre- or postoperative
positive SARS-CoV-2 status was associated with a greater 30-day
postoperative, overall mortality rate and a 3.4-fold (95% CI
Table II
Description Of SARS-Cov-2 positive survivors and nonsurvivors (unmatched cohort)
SARS-CoV-2 positive patients
Survivors n ¼ 135
SARS-CoV-2 positive patients
Nonsurvivors n ¼ 26
P value
Patient characteristics
Age categoryeno (%) <.001
<50 y 14 (10.4) 0 (0.0)
50e<70 y 49 (36.6) 2 (7.7)
70 y 71 (53.0) 24 (92.3)
Female sexeno (%) 62 (45.9) 10 (38.5) .63
BMIeno (%) .93
<18.5 5 (3.7) 2 (7.7)
18.5e<25 40 (29.6) 9 (34.6)
25e<30 40 (29.6) 6 (23.1)
30e<35 26 (19.3) 6 (23.1)
35e<40 10 (7.4) 2 (7.7)
40 4 (3.0) 1 (3.8)
Current smokereno (%) 14 (10.4) 4 (15.4) .71
Diabeteseno (%) 32 (23.7) 12 (46.2) .04
Hypertensioneno (%) 64 (47.4) 16 (61.5)
Congestive heart failureeno (%) 7 (5.2) 6 (23.1)
Myocardial infarcteno (%) 13 (9.6) 8 (30.3) .27
Peripheral vascular diseaseeno (%) 16 (11.9) 10 (38.5) .002
Chronic pulmonary diseaseeno (%) 14 (10.4) 6 (23.1) .14
CVAeno (%) 18 (13.3) 6 (23.1) .33
Chronic renal diseaseeno (%) 15 (11.1) 7 (26.9) .07
Cancereno (%) 26 (19.3) 4 (15.4) .85
Transplanteno (%) 0 (0.0) 1 (3.8) 1.00
Immunosuppressioneno (%) 9 (6.7) 1 (3.8) .92
ECOG score .002
0e1 84 (62.2) 9 (34.6)
2 22 (16.3) 4 (15.4)
3e4 19 (14.1) 11 (42.3)
Charlson comorbidity indexemedian (IQR) 4.0 (2.0e6.0) 6.5 (4.0e8.9) .001
Surgery characteristics
ASA classificationeno (%) .02
IeII 56 (41.5) 4 (15.4)
IIIeIV 75 (55.6) 22 (84.6)
Anesthesiaeno (%) .79
General 100 (74.1) 18 (69.2)
Other (including spinal) 35 (25.9) 8 (30.8)
Type of operationeno (%) 1.00
Elective 73 (54.1) 14 (53.8)
Emergency 61 (45.2) 12 (46.2)
Surgical risk scoreeno (%) .06
1e2 39 (38.9) 3 (11.5)
3 47 (34.8) 17 (65.4)
4 31 (23.0) 5 (19.2)
5 9 (6.7) 1 (3.8)
SARS-CoV-2 characteristics
Timing of diagnosiseno (%) .001
Preoperative 67 (49.6) 2 (7.7)
Postoperative 68 (50.4) 24 (92.3)
Symptomatologyeno (%) 1.00
Asymptomatic 9 (6.7) 2 (7.7)
1 symptom 117 (86.7) 23 (88.5)
BMI, body mass index; CVA, cerebrovascular accident; ECOG, Eastern Cooperative Oncology Group.
P.K.C. Jonker et al. / Surgery 169 (2021) 264e274 2691.5e8.5) increased overall mortality risk compared with matched
control patients with a negative SARS-CoV-2 status. SARS-CoV-2
positive patients develop a greater number and more serious
postoperative complications. Pulmonary complications and
thromboembolic events are more prevalent in patients with peri-
operative SARS-CoV-2. Although several previous studies sug-
gested this increase in mortality and morbidity, this is the first
study to use a well-matched control group to provide good,
evidence-based support for this clinical observation.
In this study, 30-day overall mortality rate in the unmatched
SARS-CoV-2 positive cohort was 16% compared with 4% in the
surgical control group. SARS-CoV-2 positive patients included in
our study had a median age of 72 years. The worldwide COVID-19
overall case fatality rate for SARS-CoV-2 positive patients of the
same age category 8%.18 The increasedmortality rate of SARS-CoV-2positive patients in this age category who underwent surgery
might be attributed to a synergistic effect of SARS-CoV-2 and sur-
gery. The 30-day mortality rate of surgical patients with a periop-
erative SARS-CoV-2 infection in our study is less than the
previously reported 20.5e23.8% mortality rates.4,19,20 The differ-
encemay be attributed to the fact that we included patients treated
in a health care systemwith negligible quality differences between
hospitals with similar circumstances and time frame.
The underlying pathophysiologic mechanisms of the increased
mortality rate of SARS-CoV-2 positive patients undergoing surgery is
still unknown. Mechanical ventilation, anesthesia itself, or tissue
damage caused by the operation may each provoke a proin-
flammatory cytokine and immunosuppressive response, potentially
worsening the presentation of a pre- or postoperative SARS-CoV-
infection.19,21 Surgery-related thromboembolic and pulmonary
Table III
30-d outcomes
Unmatched patients P value Propensity score-matched patients P value
SARS-CoV-2 positive
patients n ¼ 161
SARS-CoV-2 negative
patients n ¼ 342
SARS-CoV-2 positive
patients n ¼ 123
SARS-CoV-2 negative
patients n ¼ 196
30-d postoperative mortality
30-d follow-upeno (%) <.001 <.001
Alive at hospital 26 (16.1) 25 (7.3) 21 (17.1) 13 (6.6)
Alive at rehabilitation 35 (21.7) 21 (6.1) 25 (20.3) 16 (8.2)
Alive at home 74 (46.0) 282 (82.5) 62 (50.4) 158 (80.6)
Deceased 26 (16.2) 14 (4.1) 15 (12.2) 9 (4.6)
30-d postoperative complications
Number of complications per patient,
median (IQR)
1 (0e3) 0 (0e1) <.0001 1 (0e2) 0 (0e1) <.001
Comprehensive complication index,
median (IQR)
20.9 (0e42.7) 0 (0e20.9) <.0001 20.9 (0e39.5) 0 (0e12.2) <.0001
Pulmonary complicationseno (%) 39 (24.2) 11 (3.2) <.0001 25 (20.3) 6 (3.1) <.0001
Thromboembolic complicationseno
(%)
11 (6.8) 1 (0.3) <.0001 8 (6.5) 1 (0.5) .004
Hemorrhagic complicationse no (%) 22 (13.6) 28 (8.2) .052 16 (9.9) 20 (10.2) .49
Infectious complicationseno (%) 13 (8.1) 27 (7.8) .97 11 (8.9) 12 (6.1) .42
P.K.C. Jonker et al. / Surgery 169 (2021) 264e274270complications in addition to the underlying effects of the SARS-CoV-
2 infection may further increase the risk of thrombotic effects in the
pulmonary circulation, respiratory insufficiency, respiratory distress
syndrome, and eventually death.20,22We found amortality rate of 4%
in the SARS-CoV-2 negative control group, which is twice as high
compared with the rate of 2% reported in a Dutch national registry
that studied 3.7 million elective cases of patients undergoing surgery
over a 15 year period.6 This differencemay be caused by the inclusion
of patients undergoing emergency surgery or the selection of pa-
tients with more urgent indications to undergo elective operations
during the pandemic. The rate of pulmonary complications in SARS-
CoV-2 positive patients included in our study (24%) is less than
previous studies (41%e51%) in patients with perioperative SARS-
CoV-2. The reason for this lesser rate is unclear but might be
attributed to either under or over reporting or different character-
istics of included patients. It is likely that pulmonary complications
are a direct consequence of SARS-CoV-2, potentially increased in
severity by an operation or anesthesia.4,7 Little is known about
increased postoperative thromboembolic events in SARS-CoV-2. It is
suggested that that the coagulopathy associated with COVID-19
might be attributed to a combination of disseminated intravascular
coagulation and localized pulmonary thrombotic microangiopathy.23
Thromboembolic events have been described previously as a major
risk factor for mortality in hospitalized patients with SARS-CoV2.24,25
Future studies with larger cohorts of surgical patients are needed to
further confirm our observations and assess the association between
thromboembolic events and postoperative mortality.
Comparing outcomes of surgery between hospitals within a
uniform health care system allows for accurate assessment of dif-
ferences in morbidity and mortality between SARS-CoV-2 positive
and negative patients. We used propensity score matching in an
attempt to account for a wide variety of baseline differences. Our
study still, however, has limitations we need to address. Despite the
propensity matching, it is still possible that some amount of un-
measured confounding remains. The SARS-CoV-2 positive cohort is
a heterogeneous group, consisting of asymptomatic and symp-
tomatic patients diagnosed pre- or postoperatively. Especially at
the beginning of the first wave of SARS-CoV-2 infections in the
Netherlands, testing capacity was limited, and patients could not be
screened routinely before their operation. This reality is reflected
by the proportion of patients with a postoperative SARS-CoV-2
status within the 30 days postoperatively. It is likely that many,
perhaps most of the patients with a positive postoperative SARS-
CoV-2 status, were already infected during the index operation;however, the exact number of patients with a preoperative SARS-
CoV-2 status is unknown, because a proportion of preoperative
SARS-CoV-2 infections was diagnosed postoperatively. Addition-
ally, the median SARS-CoV-2 incubation period from time to
symptom onset is 5 days, whichmay further bias the differentiation
between preoperative, postoperative, in-hospital, and out-of-
hospital infections.26,27 Unfortunately, we cannot dissect out
these possibilities. Routine preoperative testing was implemented
nationally as standard of care from April onward.8 Furthermore,
because screening for SARS-CoV-2 was also not performed
routinely after surgery, it is likely that patients with an unexpected
adverse postoperative course were more prone to be tested for
SARS-CoV-2, compared with patients with an unknown asymp-
tomatic positive SARS-CoV-2 status, potentially leading to an over-
reported mortality and morbidity rate. Additionally, the elective
surgery capacity in the Netherlands during the initial wave of SARS-
CoV-2 was severely impaired. Semiurgent operations, however,
were still performed without evidence of the potential risk of a
SARS-CoV-2 infection in combination with surgery. Therefore, pa-
tients who underwent surgical interventions in this timeframe are
not representative of the general population undergoing elective
surgery before the pandemic. Probably, based on the limited elec-
tive capacity in the hospitals, surgeons prioritized more urgent
elective procedures such as semiacute cancer and trauma surgery.
The findings of this study have direct implications for the
perioperative delivery of health care, because medical pro-
fessionals across the world will be confronted continuously with
SARS-CoV-2 until effective vaccination programs have been
established or herd immunity is reached. The high morbidity and
mortality risk among perioperative SARS-CoV2 positive patients
should be an argument to postpone elective operations and even
reconsider emergency operative interventions in selected pa-
tients, especially those at risk for pulmonary or thromboembolic
complications. Surgeons on call will have to cope with acute di-
lemmas and at least consider alternative strategies to operative
intervention. Surgical strategies in SARS-CoV-2 positive patients
in need of emergency surgery may be changed toward a conser-
vative approach; for instance, antibiotics for appendicitis or acute
cholecystitis may be chosen instead of operative therapy. Results
of our study further underline the relevance of preoperative
testing of all patients in areas that have a high risk of SARS-CoV-2
infection. Current Dutch consensus documents advise to double
the dosage of thromboembolic prophylaxis of SARS-CoV-2 posi-
tive patients during ICU admission with respect to the risk of
P.K.C. Jonker et al. / Surgery 169 (2021) 264e274 271bleeding.28 The high rate of postoperative thromboembolic events
in SARS-CoV-2 positive patients undergoing operations might
address the need for personalized protocols of thromboembolic
prophylaxis in this patient category. Models of surgical risk
stratification tailored to individual SARS-CoV-2 patients are
needed. Previously established risk stratification systems, such as
the Charlson comorbidity index, the ASA score, or performance
scores might be useful tools to estimate potential postoperative
mortality in SARS-CoV-2 positive patients diagnosed preopera-
tively. Therefore, it remains highly relevant to collaborate globally
and to share and analyze outcomes of surgery in the SARS-CoV-2
positive population in future studies.4
In conclusion, this nationwide, matched cohort study shows
that a pre- or postoperative SARS-CoV-2 positive status increases
30-day overall postoperative mortality rates, pulmonary compli-
cations, and thromboembolic events in patients undergoing
operative care. The results of this study provide further evidence
that elective operations in patients with preoperatively diagnosed
SARS-CoV-2 should be postponed whenever possible and even
emergency operative intervention for selected patients should be
carefully reconsidered. Altered protocols of thromboembolic
prophylaxis might be required to prevent thromboembolic com-
plications in surgical patients with SARS-CoV-2, but the use of
greater than the normal dosage of thromboembolic prophylaxis
should be carefully weighed against the risk of (postoperative)
bleeding.Dutch Surgical COVID-19 Research Collaborative Co-Authors
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